Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Diana T Samuels, Brian J. Ball, NI-Chun Tsai, Amanda Blackmon, Vaibhav Agrawal, Hoda Pourhassan, Idoroenyi Amanam, Paul B. Koller, Shukaib Arslan, Salman Otoukesh, Karamjeet S Sandhu, Ibrahim Aldoss, Haris Ali, Amandeep Salhotra, MHD Monzr M. Al Malki, Andrew Artz, Pamela S. Becker, Ahmed Aribi, Eileen Patricia Smith, Stephen J. Forman, Anthony S. Stein, Guido Marcucci, Ryotaro Nakamura, Vinod Pullarkat
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405038324